FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gary Hudes

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Yu-Ning Wong; Marion Brody; Seth Cohen; Michael Dabrow; James Lee; Samuel Litwin; Elizabeth R Plimack; Wei Song; Holly Tuttle; David Vaughn; Gary R Hudes
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.
M Dror Michaelson; A Nieto; I Pardos; C A Stein; J Bellmunt; M Cullell-Young; S Goel; Gary R Hudes; Carmen Kahatt; Philip W Kantoff; P Lardelli; R J Lee; Nancy L Lewis; Matthew R Smith
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.
Robert J Motzer; Mark R Olsen; John A Thompson; Olga Valota; George Wilding; Jinyu Yuan; Neeraj Agarwal; Akintunde Bello; John M Burke; David Cella; William J Edenfield; Subramanian Hariharan; Gary R Hudes; Thomas E Hutson; Beata Korytowsky; Bridget Martell; Robert A Figlin
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gary Hudes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Yu-Ning Wong; Marion Brody; Seth Cohen; Michael Dabrow; James Lee; Samuel Litwin; Elizabeth R Plimack; Wei Song; Holly Tuttle; David Vaughn; Gary R Hudes
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(28):3545-51.
2012: M Dror Michaelson; A Nieto; I Pardos; C A Stein; J Bellmunt; M Cullell-Young; S Goel; Gary R Hudes; Carmen Kahatt; Philip W Kantoff; P Lardelli; R J Lee; Nancy L Lewis; Matthew R Smith
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(5):1234-40.
2012: Robert J Motzer; Mark R Olsen; John A Thompson; Olga Valota; George Wilding; Jinyu Yuan; Neeraj Agarwal; Akintunde Bello; John M Burke; David Cella; William J Edenfield; Subramanian Hariharan; Gary R Hudes; Thomas E Hutson; Beata Korytowsky; Bridget Martell; Robert A Figlin
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(12):1371-7.
2012: Robert J Motzer; Thomas Olencki; Roberto Pili; Thomas W Ratliff; Bruce G Redman; Cary N Robertson; Charles J Ryan; Joel Sheinfeld; Jue Wang; Richard B Wilder; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Mark K. Buyyounouski; Michael A Carducci; Sam S Chang; Toni K Choueiri; Shilpa Gupta; Steven L Hancock; Gary R Hudes; Eric Jonasch; Timothy M Kuzel; Clayton Lau; Ellis G Levine; Daniel W Lin; Kim A Margolin; M Dror Michaelson
Testicular cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2012;10(4):502-35.
2011: Aladdin Mustafa; Robert G Uzzo; Brian L Egleston; Sapna Gupta; Gary R Hudes; warren kruger
Serum amino acid levels as a biomarker for renal cell carcinoma.
The Journal of urology 2011;186(4):1206-12.
2011: Elizabeth R Plimack; Gary R Hudes
Selecting targeted therapies for patients with renal cell carcinoma.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(9):997-1006; quiz 1007.
2011: Robert J Motzer; Thomas Olencki; Roberto Pili; Thomas W Ratliff; Bruce G Redman; Cary N Robertson; Charles J Ryan; Joel Sheinfeld; Philippe E Spiess; Jue Wang; Richard B Wilder; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Michael A Carducci; Sam S Chang; Toni K Choueiri; Steven L Hancock; Gary R Hudes; Eric Jonasch; David Josephson; Timothy M Kuzel; Ellis G Levine; Daniel W Lin; Kim A Margolin; M Dror Michaelson
Kidney cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(9):960-77.
2011: Jose Pablo Maroto; Gary R Hudes; Janice P Dutcher; Theodore F Logan; Charles S White; Mizue Krygowski; Maria Cincotta; Mark Shapiro; Ignacio Duran; Anna Berkenblit
Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(13):1750-6.
2010: Ilsiya Ibragimova; Inmaculada Ibáñez de Cáceres; Amanda M Hoffman; Anna Potapova; Essel Dulaimi; Tahseen Al-Saleem; Gary R Hudes; Michael Ochs; Paul Cairns
Global reactivation of epigenetically silenced genes in prostate cancer.
Cancer prevention research (Philadelphia, Pa.) 2010;3(9):1084-92.
2010: Jianming Pei; Madelyn M Feder; Tahseen Al-Saleem; Zemin Liu; Angen Liu; Gary R Hudes; Robert G Uzzo; Joseph R Testa
Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma.
Genes, chromosomes & cancer 2010;49(7):610-9.
2009: Gary R Hudes; Anna Berkenblit; Jay Feingold; Michael B Atkins; Brian I Rini; Janice Dutcher
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Seminars in oncology 2009;36 Suppl 3():S26-36.
2009: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang
NCCN clinical practice guidelines in oncology: kidney cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(6):618-30.
2009: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang
NCCN clinical practice guidelines in oncology: testicular cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(6):672-93.
2009: Gary R Hudes
Targeting mTOR in renal cell carcinoma.
Cancer 2009;115(10 Suppl):2313-20.
2009: James E Montie; Peter E Clark; Mario A Eisenberger; Rizk El-Galley; Richard E Greenberg; Harry W Herr; Gary R Hudes; Deborah A Kuban; Timothy M Kuzel; Paul H Lange; Subodh M Lele; Jeffrey Michalski; Anthony Patterson; Kamal S Pohar; Jerome P Richie; Wade J Sexton; William U Shipley; Eric J Small; Donald L Trump; Phillip J Walther; Timothy G Wilson
Bladder cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(1):8-39.
2009: Yu-Ning Wong; Stephen Freedland; Brian Egleston; Gary R Hudes; J Sanford Schwartz; Katrina A Armstrong
Role of androgen deprivation therapy for node-positive prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):100-5.
2007: Olivier Rixe; Ronald M Bukowski; M Dror Michaelson; George Wilding; Gary R Hudes; Oliver Bolte; Robert J Motzer; Paul Bycott; Katherine F Liau; James Freddo; Peter C Trask; Sinil Kim; Brian I Rini
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
The lancet oncology 2007;8(11):975-84.
2007: Robert J Motzer; M Dror Michaelson; Jonathan Rosenberg; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; George Wilding
Sunitinib efficacy against advanced renal cell carcinoma.
The Journal of urology 2007;178(5):1883-7.
2007: Samuel Litwin; Yu-Ning Wong; Gary R Hudes
Early stopping designs based on progression-free survival at an early time point in the initial cohort.
Statistics in medicine 2007;26(24):4400-15.
2007: Gary R Hudes
mTOR as a target for therapy of renal cancer.
Clinical advances in hematology & oncology : H&O 2007;5(10):772-4.
2007: Robert J Motzer; Gary R Hudes; Brendan D Curti; David F McDermott; Bernard Escudier; Sylvie Negrier; Brigitte Duclos; Laurence Moore; Timothy O'Toole; Joseph P Boni; Janice P Dutcher
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3958-64.
2007: Gary R Hudes; Michael A Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey A Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
The New England journal of medicine 2007;356(22):2271-81.
2006: Yu-Ning Wong; Nandita Mitra; Gary R Hudes; Russell Localio; J Sanford Schwartz; Fei Wan; Chantal Montagnet; Katrina A Armstrong
Survival associated with treatment vs observation of localized prostate cancer in elderly men.
JAMA : the journal of the American Medical Association 2006;296(22):2683-93.
2006: Raymond S McDermott; Dwight D Kloth; Hao Wang; Gary R Hudes; Corey J Langer
Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model.
The journal of supportive oncology 2006;4(10):524-9.
2006: Robert J Motzer; Graeme B Bolger; Barry Boston; Michael A Carducci; Mayer Fishman; Steven L Hancock; Ralph J Hauke; Gary R Hudes; Eric Jonasch; Philip W Kantoff; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Chris Logothetis; Kim A Margolin; Kamal S Pohar; Bruce G Redman; Cary N Robertson; Wolfram E Samlowski; Joel Sheinfeld
Kidney cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(10):1072-81.
2006: Robert J Motzer; Graeme B Bolger; Barry Boston; Michael A Carducci; Mayer Fishman; Steven L Hancock; Ralph J Hauke; Gary R Hudes; Eric Jonasch; Philip W Kantoff; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Chris Logothetis; Kim A Margolin; Kamal S Pohar; Bruce G Redman; Cary N Robertson; Wolfram E Samlowski; Joel Sheinfeld
Testicular cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(10):1038-58.
2006: Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson
Sunitinib in patients with metastatic renal cell carcinoma.
JAMA : the journal of the American Medical Association 2006;295(21):2516-24.
2006: Mary Cianfrocca; K A Kimmel; James Gallo; T Cardoso; M M Brown; Gary R Hudes; Nancy Lewis; L Weiner; G N Lam; S C Brown; David E Shaw; Andrew P Mazar; Roger B Cohen
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.
British journal of cancer 2006;94(11):1621-6.
2006: Robert J Motzer; M Dror Michaelson; Bruce G Redman; Gary R Hudes; George Wilding; Robert A Figlin; Michelle S Ginsberg; Sindy T Kim; Charles M Baum; Samuel E DePrimo; Jim Z Li; Carlo L Bello; Charles P Theuer; Daniel J George; Brian I Rini
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):16-24.
2005: André Rogatko; James S Babb; Mourad Tighiouart; Fadlo R Khuri; Gary R Hudes
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5342-6.
2005: Michael Burczynski; Natalie C Twine; Gary Dukart; Bonnie Marshall; Manuel Hidalgo; Walter M Stadler; Theodore Logan; Janice Dutcher; Gary R Hudes; William L Trepicchio; Andrew Strahs; Fred Immermann; Donna K Slonim; Andrew J Dorner
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):1181-9.
2005: Robert J Motzer; Michael A Carducci; Mayer Fishman; Steven L Hancock; Ralph J Hauke; Gary R Hudes; Philip Kantoff; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Chris Logothetis; Kim A Margolin; Roberto Pili; Kamal S Pohar; Bruce G Redman; Sylvia Richey; Cary N Robertson; Wolfram E Samlowski; Joel Sheinfeld; Donald A Urban
Kidney cancer. Clinical practice guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(1):84-93.
2005: Robert J Motzer; Robert R Bahnson; Barry Boston; Michael A Carducci; Mayer Fishman; Steven L Hancock; Ralph J Hauke; Gary R Hudes; Philip Kantoff; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Chris Logothetis; Kim A Margolin; Bruce G Redman; Sylvia Richey; Cary N Robertson; Wolfram E Samlowski; Joel Sheinfeld; Donald A Urban
Testicular cancer. Clinical practice guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(1):52-76.
2005: James E Montie; Robert R Bahnson; Samuel M Cohen; Beverly Drucker; Mario A Eisenberger; Rizk El-Galley; Harry W Herr; Gary R Hudes; Timothy M Kuzel; Paul H Lange; Anthony Patterson; Alan Pollack; Jerome P Richie; John Seigne; William U Shipley; Eric J Small; Donald L Trump; Philip J Walther; Timothy G Wilson
Bladder cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(1):4-5, 19-34.
2004: Raymond S McDermott; Penny R. Anderson; Richard E Greenberg; Barton N Milestone; Gary R Hudes
Cranial nerve deficits in patients with metastatic prostate carcinoma: clinical features and treatment outcomes.
Cancer 2004;101(7):1639-43.
2004: André Rogatko; James S Babb; Hao Wang; Michael J Slifker; Gary R Hudes
Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4645-51.
2004: Thomas J Mueller; Hong Wu; Richard E Greenberg; Gary R Hudes; Neil Topham; Stuart R Lessin; Robert G Uzzo
Cutaneous metastases from genitourinary malignancies.
Urology 2004;63(6):1021-6.
2004: Michael B Atkins; Manuel Hidalgo; Walter M Stadler; Theodore F Logan; Janice P Dutcher; Gary R Hudes; Young Park; Song-Heng Liou; Bonnie Marshall; Joseph P Boni; Gary Dukart; Matthew L Sherman
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):909-18.
2003: Naomi B Haas; Bruce Giantonio; Samuel Litwin; Carl J Minniti; Stephen Fox; Gwen Yeslow; Robert Reilly; Kenneth Nahum; Richard Greenberg; Theresa Halbherr; Gary R Hudes
Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.
Cancer 2003;98(9):1837-41.
2003: Natalie C Twine; Jennifer A Stover; Bonnie Marshall; Gary Dukart; Manuel Hidalgo; Walter Stadler; Theodore Logan; Janice Dutcher; Gary R Hudes; Andrew J Dorner; Donna K Slonim; William L Trepicchio; Michael Burczynski
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma.
Cancer research 2003;63(18):6069-75.
2003: Robert G Uzzo; Paul Cairns; Tahseen Al-Saleem; Gary R Hudes; Naomi Haas; Richard E Greenberg; Vladimir Kolenko
The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician.
The Urologic clinics of North America 2003;30(3):423-36.
2003: Steven J Cohen; Linus Ho; Sulabha Ranganathan; James L Abbruzzese; R Katherine Alpaugh; Mary Beard; Nancy L Lewis; Susan McLaughlin; André Rogatko; Juan Jose Perez-Ruixo; Amanda M Thistle; Tom Verhaeghe; Hao Wang; Louis M Weiner; John J Wright; Gary R Hudes; Neal J Meropol
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(7):1301-6.
2003: Alice K David; Radhika Khwaja; Gary R Hudes
Treatments for improving survival of patients with prostate cancer.
Drugs & aging 2003;20(9):683-99.
2003: Naomi B Haas; Mitchell Smith; Nancy Lewis; Lynn Littman; Gwen Yeslow; Indira Joshi; Anthony J Murgo; Joyce Bradley; Robert Gordon; Hao Wang; André Rogatko; Gary R Hudes
Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):109-14.
2002: Gary R Hudes
Signaling inhibitors in the treatment of prostate cancer.
Investigational new drugs 2002;20(2):159-72.
2002: Gary R Hudes; Naomi Haas; Gwen Yeslow; Thomas Gillon; Per Olov Gunnarsson; Marianne Ellman; Orjan Nordle; Brigitta Eriksson; Langdon Miller; Laura Cisar; Michael Kopreski; Donatella Viaro; Beryl Hartley-Asp
Phase I clinical and pharmacologic trial of intravenous estramustine phosphate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(4):1115-27.
2001: S Ranganathan; R A McCauley; Dwayne Dexter; Gary R Hudes
Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
British journal of cancer 2001;85(5):735-40.
2001: Naomi Haas; B Roth; CA Garay; Gwen Yeslow; M Entmacher; A Weinstein; André Rogatko; James Babb; C Minnitti; D Flinker; T Gillon; Gary R Hudes
Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.
Urology 2001;58(1):59-64.
2001: Coleman K Obasaju; Gary R Hudes
Paclitaxel and docetaxel in prostate cancer.
Hematology/oncology clinics of North America 2001;15(3):525-45.
2001: Coleman K Obasaju; J Manola; Gary R Hudes; J D Khandekar; D L Citrin; P Carbone; D L Trump
Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885.
American journal of clinical oncology 2001;24(2):150-4.
2001: Bruce Giantonio; Howard Hochster; Ronald Blum; P H Wiernik; Gary R Hudes; J Kirkwood; D Trump; Martin M Oken
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group.
Investigational new drugs 2001;19(1):89-92.
2000: Naomi B Haas; J Manola; Gary R Hudes; D L Citrin; M S Kies; T E Davis
Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer.
American journal of clinical oncology 2000;23(6):589-92.
2000: Gary R Hudes; Christine E Szarka; A Adams; S Ranganathan; R A McCauley; Louis M Weiner; Corey J Langer; Samuel Litwin; Gwen Yeslow; T Halberr; M Qian; James M Gallo
Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3071-80.
1999: Glenn J Bubley; Michael A Carducci; William Dahut; Nancy A Dawson; Danai D Daliani; Mario A Eisenberger; William D Figg; B Freidlin; Susan Halabi; Gary R Hudes; Maha Hussain; Richard S. Kaplan; C Myers; William K Oh; Daniel P Petrylak; Eddie Reed; B Roth; Oliver Sartor; Howard I Scher; J Simons; Victoria Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3461-7.
1999: Gary R Hudes; Lawrence Einhorn; Eric A Ross; A Balsham; Patrick J Loehrer; Heather Ramsey; J Sprandio; M Entmacher; W Dugan; Rafat Ansari; F Monaco; M Hanna; B Roth
Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3160-6.
1999: Gary M Freedman; William G Negendank; Gary R Hudes; AH Shaer; Gerald E Hanks
Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer.
Urology 1999;54(1):118-23.
1999: Gary R Hudes; S Lipsitz; J Grem; M Morrisey; L Weiner; J W Kugler; A Benson
A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Cancer 1999;85(2):290-4.
1998: D B Sokol; Gary R Hudes
Cisplatin-based chemotherapy for testicular cancer in a patient with spinal muscular atrophy: a case report.
American journal of clinical oncology 1998;21(4):420-1.
1998: J D Berlin; Kathleen J Propert; D Trump; G Wilding; Gary R Hudes; J Glick; P Burch; A Keller; Patrick J Loehrer
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).
American journal of clinical oncology 1998;21(2):171-6.
1998: S Ranganathan; CA Benetatos; Patrick Colarusso; Dwayne Dexter; Gary R Hudes
Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells.
British journal of cancer 1998;77(4):562-6.
1998: S Ranganathan; Dwayne Dexter; CA Benetatos; Gary R Hudes
Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents.
Biochimica et biophysica acta 1998;1395(2):237-45.
1997: Gary R Hudes; F Nathan; C Khater; Naomi Haas; M Cornfield; Bruce Giantonio; R Greenberg; L Gomella; Samuel Litwin; Eric A Ross; S Roethke; Cecilia McAleer
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(9):3156-63.
1997: S Ranganathan; H Salazar; CA Benetatos; Gary R Hudes
Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy.
The Prostate 1997;30(4):263-8.
1997: Gary R Hudes
Estramustine-based chemotherapy.
Seminars in urologic oncology 1997;15(1):13-9.
1997: N Haas; Gary R Hudes
Genitourinary malignancy.
Cancer chemotherapy and biological response modifiers 1997;17():504-35.
1997: A Hageboutros; Gary R Hudes; F Greene; F P LaCreta; J Brennan; Peter J O'Dwyer
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
Investigational new drugs 1997;15(2):139-45.
1996: S Ranganathan; Dwayne Dexter; C A Benetatos; A E Chapman; Kenneth D Tew; Gary R Hudes
Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.
Cancer research 1996;56(11):2584-9.
1996: Gerald E Hanks; A L Hanlon; Gary R Hudes; W Robert Lee; W Suasin; Timothy Schultheiss
Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1093-7.
1996: J Leighton; J Clark; Bruce Giantonio; Robert F Ozols; Gary R Hudes
Genitourinary malignancy.
Cancer chemotherapy and biological response modifiers 1996;16():524-63.
1996: A Hageboutros; Gary R Hudes; J Brennan; F Green; J Hoffman; F P LaCreta; J Colofiore; D S Martin; Robert F Ozols; Peter J O'Dwyer
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Cancer chemotherapy and pharmacology 1996;37(3):229-34.
1995: Gary R Hudes; F E Nathan; C Khater; R Greenberg; L Gomella; C Stern; Cecilia McAleer
Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
Seminars in oncology 1995;22(5 Suppl 12):41-5.
1995: Gary R Hudes; C Obasaju; A Chapman; J Gallo; Cecilia McAleer; R Greenberg
Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
Seminars in oncology 1995;22(3 Suppl 6):6-11.
1995: BW Corn; Gerald E Hanks; W Robert Lee; S R Bonin; Gary R Hudes; T Schultheiss
Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy.
The Journal of urology 1995;153(6):1855-9.
1995: Charles D. Smith; J T Zilfou; X Zhang; Gary R Hudes; Kenneth D Tew
Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins.
Cancer 1995;75(10):2597-604.
1995: Gary R Hudes; R Kosierowski; R Greenberg; H E Ramsey; S C Fox; Robert F Ozols; Cecilia McAleer; Bruce Giantonio
Phase II study of topotecan in metastatic hormone-refractory prostate cancer.
Investigational new drugs 1995;13(3):235-40.
1995: A Hageboutros; André Rogatko; E M Newman; Cecilia McAleer; J Brennan; F P LaCreta; Gary R Hudes; Robert F Ozols; Peter J O'Dwyer
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Cancer chemotherapy and pharmacology 1995;35(3):205-12.
1994: L A Speicher; L R Barone; A E Chapman; Gary R Hudes; N Laing; Charles D. Smith; Kenneth D Tew
P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine.
Journal of the National Cancer Institute 1994;86(9):688-94.
1994: N B Haas; F P LaCreta; J Walczak; Gary R Hudes; J M Brennan; Robert F Ozols; Peter J O'Dwyer
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Cancer research 1994;54(5):1220-6.
1994: Gary R Hudes; Robert F Ozols; Bruce Giantonio
Genitourinary malignancy.
Cancer chemotherapy and biological response modifiers 1994;15():531-54.
1993: N B Haas; J B Hines; Gary R Hudes; N Johnston; Robert F Ozols; Peter J O'Dwyer
Phase I trial of 5-fluorouracil by 24-hour infusion weekly.
Investigational new drugs 1993;11(2-3):181-5.
1993: Louis M Weiner; Gary R Hudes; J Kitson; J Walczak; P Watts; Samuel Litwin; Peter J O'Dwyer
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Cancer immunology, immunotherapy : CII 1993;36(3):185-90.
1993: Bruce Giantonio; Robert F Ozols; Gary R Hudes
Genitourinary malignancy.
Cancer chemotherapy and biological response modifiers 1993;14():498-529.
1992: Peter J O'Dwyer; Gary R Hudes; J Walczak; Russell J Schilder; F LaCreta; B Rogers; I Cohen; C Kowal; L Whitfield; R A Boyd
Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
Cancer research 1992;52(24):6746-53.
1992: Kenneth D Tew; J P Glusker; Beryl Hartley-Asp; Gary R Hudes; L A Speicher
Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug.
Pharmacology & therapeutics 1992;56(3):323-39.
1992: Gary R Hudes; R Greenberg; R L Krigel; S Fox; R Scher; Samuel Litwin; P Watts; L Speicher; Kenneth D Tew; R Comis
Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1754-61.
1992: Peter J O'Dwyer; F P LaCreta; Russell J Schilder; S Nash; Cecilia McAleer; L L Miller; Gary R Hudes; Robert F Ozols
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(8):1352-8.
1991: Peter J O'Dwyer; Gary R Hudes; J Colofiore; J Walczak; J Hoffman; F P LaCreta; R L Comis; D S Martin; Robert F Ozols
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
Journal of the National Cancer Institute 1991;83(17):1235-40.
1991: Gary R Hudes; F LaCreta; J Walczak; P Tinsley; Samuel Litwin; R L Comis; Peter J O'Dwyer
Pharmacokinetic study of trimetrexate in combination with cisplatin.
Cancer research 1991;51(12):3080-7.
1991: Peter J O'Dwyer; A R Paul; Gary R Hudes; J Walczak; Robert F Ozols; R L Comis
Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
Investigational new drugs 1991;9(1):65-7.
1991: Peter J O'Dwyer; Corey J Langer; J Walczak; Michael H Levy; K Padavic-Shaller; Gary R Hudes; Samuel Litwin; R L Comis
Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1589-93.
1989: Gary R Hudes; F LaCreta; R J DeLap; A J Grillo-Lopez; R Catalano; R L Comis
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Cancer chemotherapy and pharmacology 1989;24(2):117-22.
1988: V S Schwob; L Weiner; Gary R Hudes; Howard Ratech
Extranodal non-T-cell lymphoblastic lymphoma in adults. A report of two cases.
American journal of clinical pathology 1988;90(5):602-5.
1988: Gary R Hudes; R L Comis
Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer.
Seminars in oncology 1988;15(2 Suppl 2):41-5.